Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Diverticulosis, its associated symptoms and complications are one of the most common pathologies of the gastrointestinal tract in more economically developed countries. Presence of diverticuli and their clinical consequences can be divided into four categories: 1) diverticulosis, i.e. an asymptomatic presence of diverticuli that are usually found by accident 2) symptomatic uncomplicated diverticulosis 3) diverticulitis (acute uncomplicated diverticulitis) 4) complications of diverticulitis (conditions requiring hospital stay). The aim of this study was to retrospectively analyze the efficacy of rifaximin in preventing diverticulitis in patients visiting proctology clinics. The diagnostic criterium for diverticulosis was confirmation by colonoscopy, barium enema or CT colography (virtual colonoscopy) as well as history of at least one documented episode of diverticulosis. History of diverticulosis was evaluated based on medical records, clinical symptoms, elevated level of CRP (>5.0) and/or diagnostic imaging (ultrasound, CT). After setting strict exclusion criteria, 248 patients were qualified for the study out of 686, and they were later divided into two groups: control group (group I - 145 patients) and studied group (group II - 103 patients receiving rifaximin prophylaxis). Diverticulitis rate was comparable in both groups over a period of 6 months before study (p = 0.1306) and 6 months of treatment (p=0.3044). Between the 6th and 12th month of treatment, a significantly lower rate of diverticulitis was noted in the group receiving rifaximin compared to control group (p<0.0001). Patients receiving rifaximin reported higher quality of life (which was assessed using the VAS scale) compared to control group after 12 months. The results confirmed the efficacy of riaximin in prevention of diverticulitis, even in the scheme of repeated courses every 3 months. Not only did application of rifaximin lower the rate of diverticulitis and its complications in patients after an episode of diverticulitis, but also it improved the patients' quality of life. It seems that diverticulitis prophylaxis based on rifaximin can be economically efficient, however, it requires further research.

      Related collections

      Author and article information

      Affiliations
      [1 ] Klinika Chirurgii Ogólnej, Endokrynologicznej i Onkologii Gastroenterologicznej, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Państwowa Wyższa Szkoła Zawodowa im. Prezydenta Stanisława Wojciechowskiego w Kaliszu.
      [2 ] Klinik für Dermatologie, Venerologie und Allergologie; Charité Universitätsmedzin Berlin, Deutschland.
      [3 ] Klinika Chirurgii Ogólnej, Endokrynologicznej i Onkologii Gastroenterologicznej, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
      [4 ] Department of General Surgery Rutgers New Jersey Medical School, Newark, USA.
      [5 ] Klinika Chirurgii Ogólnej i Kolorektalnej, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
      [6 ] Kliniczny Oddział Chirurgii Ogólnej i Kolorektalnej Szpitala Bielańskiego w Warszawie Wydział Rehabilitacji Akademii Wychowania Fizycznego Józefa Piłsudskiego w Warszawie.
      [7 ] Klinika Chirurgii Ogólnej, Kolorektalnej i Urazowej, Szpital Św. Barbary w Sosnowcu.
      Journal
      Pol Przegl Chir
      Polski przeglad chirurgiczny
      Index Copernicus
      2299-2847
      0032-373X
      Feb 28 2017
      : 89
      : 1
      28522790
      10.5604/01.3001.0009.6012
      01.3001.0009.6012

      Comments

      Comment on this article